SLGL
Sol-gel·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SLGL
Sol-Gel Technologies Ltd.
A dermatology company focused on generic topical drug products for the treatment of skin diseases
7 Golda Meir St., Weizmann Science Park , Ness Ziona, 7403650, Israel
--
Sol-gel Technologies Ltd. Incorporated under the laws of the State of Israel on October 28, 1997. The company is an innovative dermatology company with a successful track record of two NDA approvals and a pipeline of advanced product candidates under development for orphan indications. Sol-Gel successfully developed pioneering topical drugs Twyneo and Epsolay, which were approved for the treatment of rosacea and inflammatory lesions, respectively.
Company Financials
EPS
SLGL has released its 2025 Q3 earnings. EPS was reported at -2.13, versus the expected -2.09, missing expectations. The chart below visualizes how SLGL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SLGL has released its 2025 Q3 earnings report, with revenue of 400.00K, reflecting a YoY change of -92.54%, and net profit of -5.94M, showing a YoY change of -1523.50%. The Sankey diagram below clearly presents SLGL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
